Targeting the MEK and STAT3 Pathways in Combination With PD1 Blockade Immunotherapy in KRAS-mutant Pancreatic Cancer

被引：0
|
作者：
Mehra, S. [1 ]
Lamichhane, P. [1 ,2 ]
Messaggio, F. [1 ]
Dai, X. [1 ]
Dosch, A. [1 ]
Willobee, B. [1 ]
Srinivasan, S. [1 ]
VanSaun, M. N. [1 ,3 ]
Nagathihalli, N. [1 ,3 ]
Merchant, N. [1 ,3 ]
机构：
[1] Univ Miami, Miller Sch Med, Dept Surg, Miami, FL 33136 USA
[2] LECOM Sch Dent Med, Bradenton, FL USA
[3] Univ Miami, Miller Sch Med, Sylvester Comprehens Canc Ctr, Miami, FL 33136 USA
来源：
PANCREAS | 2019年 / 48卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：1490 / 1490
页数：1
相关论文
共 50 条
  • [31] A MEK/PI3K/HDAC inhibitor combination therapy for KRAS mutant pancreatic cancer cells
    Ischenko, Irene
    Petrenko, Oleksi
    Hayman, Michael J.
    ONCOTARGET, 2015, 6 (18) : 15814 - 15827
  • [32] Targeting Established Lung Cancer Through Combination of DNT Cellular Therapy with PD1 Checkpoint Blockade
    Fang, L.
    Ly, D.
    Liu, W.
    Wang, S.
    Lee, J.
    Kang, H.
    Zhang, L.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S525 - S526
  • [33] Implication of targeting YAP1 in KRAS-mutant lung cancer cells.
    Shimomura, Iwao
    Yamamoto, Yusuke
    Tada, Yuji
    Tatsumi, Koichiro
    Ochiya, Takahiro
    MOLECULAR CANCER RESEARCH, 2020, 18 (08) : 39 - 40
  • [34] Oncogenic dependency on STAT3 serine phosphorylation in KRAS mutant lung cancer
    Sultan Alhayyani
    Louise McLeod
    Alison C. West
    Jesse J. Balic
    Christopher Hodges
    Liang Yu
    Julian A. Smith
    Zdenka Prodanovic
    Steven Bozinovski
    Beena Kumar
    Saleela M. Ruwanpura
    Mohamed I. Saad
    Brendan J. Jenkins
    Oncogene, 2022, 41 : 809 - 823
  • [35] Oncogenic dependency on STAT3 serine phosphorylation in KRAS mutant lung cancer
    Alhayyani, Sultan
    McLeod, Louise
    West, Alison C.
    Balic, Jesse J.
    Hodges, Christopher
    Yu, Liang
    Smith, Julian A.
    Prodanovic, Zdenka
    Bozinovski, Steven
    Kumar, Beena
    Ruwanpura, Saleela M.
    Saad, Mohamed I.
    Jenkins, Brendan J.
    ONCOGENE, 2022, 41 (06) : 809 - 823
  • [36] Triple Blockade of Oncogenic RAS Signaling Using KRAS and MEK Inhibitors in Combination with Irradiation in Pancreatic Cancer
    Wang, Xuan
    Breuer, Johanna
    Garbe, Stephan
    Giordano, Frank
    Brossart, Peter
    Feldmann, Georg
    Bisht, Savita
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (11)
  • [37] Targeting the STAT3 oncogenic pathway: Cancer immunotherapy and drug repurposing
    Dong, Yushan
    Chen, Jingyu
    Chen, Yuhan
    Liu, Songjiang
    BIOMEDICINE & PHARMACOTHERAPY, 2023, 167
  • [38] Eicosapentaenoic Acid Inhibits KRAS Mutant Pancreatic Cancer Cell Growth by Suppressing Hepassocin Expression and STAT3 Phosphorylation
    Chiu, Ching-Feng
    Hsu, Ming-, I
    Yeh, Hsiu-Yen
    Park, Ji Min
    Shen, Yu-Shiuan
    Tung, Te-Hsuan
    Huang, Jun-Jie
    Wu, Hung-Tsung
    Huang, Shih-Yi
    BIOMOLECULES, 2021, 11 (03) : 1 - 17
  • [39] KRAS mutant lung cancer cells are differentially responsive to MEK inhibition due to AKT or STAT3 activation: Implication for combinatorial approach
    Yoon, Young-Kwang
    Kim, Hwang-Phill
    Han, Sae-Won
    Im, Seock-Ah
    Oh, Do Youn
    Bang, Yung-Jue
    Kim, Tae-You
    MOLECULAR CANCER THERAPEUTICS, 2009, 8 (12)
  • [40] KRAS Mutant Lung Cancer Cells Are Differentially Responsive to MEK Inhibitor Due to AKT or STAT3 Activation: Implication for Combinatorial Approach
    Yoon, Young-Kwang
    Kim, Hwang-Phill
    Han, Sae-Won
    Oh, Do Youn
    Im, Seock-Ah
    Bang, Yung-Jue
    Kim, Tae-You
    MOLECULAR CARCINOGENESIS, 2010, 49 (04) : 353 - 362
12345